Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Blood Glucose Monitoring Market (2012 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 105 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 105 pages
- Published: 12-06-2019
Market Overview
The global blood glucose monitoring market is expected to register a CAGR of 11.88% during the forecast period of 2019 – 2024; the market is estimated to reach USD 12.8 billion by 2019.
Blood glucose monitoring devices are used for effective diabetes diagnosis and treatment. A rise in the diabetic population drives the market by increasing the use of blood glucose monitoring devices.
Obesity is also considered as one of the major factors contributing to the disease, primarily Type 2 diabetes.
Also, other factors, such as technological innovations and advancements, give much convenience in measuring the blood glucose levels. One such advancement in monitoring the blood glucose level is established with continuous glucose monitoring devices.
These devices help in the early detection of hypo and hyperglycemic conditions, which tend to drive the market for glucose monitoring.
Scope of the Report
There are two main types of blood glucose monitoring devices included in this study, namely the self monitoring blood glucose devices and the continuous glucose monitoring devices. The devices are further categorized by components, i.e. the self-monitoring blood glucose (SMBG) devices are segmented into glucometer devices, test strips, and lancets (which are further studied by their usage in hospital and home individually) and continuous glucose monitoring (CGM) devices are segmented into sensors and receivers.
Key Market Trends
Glucometer consumables (test strips and lancets) occupy the highest market share
Although CGM is an advanced way for people living with diabetes to check glucose readings in real-time, SMBG is the most preferred device by the patients due to its economic affordability and less sophisticated usage when compared to CGM. The SBGM occupies more than 87% of the share in the blood glucose monitoring market. The further segmented market of SBGM gives an understanding that the disposable consumables – test strips and lancets, occupy the larger market share when compared to glucometer devices. However, the CAGR for glucometer devices is high.
CGM, though it provides real-time data of blood glucose levels for patients, has low adaptability in the emerging markets. However, CGM’s adaptability is high in developed markets. The cost factor is a major concern for the low growth of CGM in emerging markets.
North America is leading the market
In 2018, North America, especially the United States, held the largest share in the blood glucose monitoring market, due to the large patient pool and wide acceptance of advanced technologies followed by Europe, which showed moderate growth. Asia-Pacific, Latin America, and the Middle East & Africa showed low growth due to economic affordability.
Competitive Landscape
The blood glucose monitoring market is highly fragmented with few major manufacturers boasting a global market presence, while the remaining manufacturers confining to the other local or region-specific manufacturers.
Mergers and acquisitions that happened between the players in the recent past helped the companies to strengthen their market presence. For example, Dexcom has partnered with Julphar to have its market presence in the Middle Eastern region.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Blood Glucose Monitoring
5.1.1 Self-Monitoring Blood Glucose
5.1.1.1 By Component (Market Size, Value and Volume)
5.1.1.1.1 Glucometer Devices
5.1.1.1.2 Test Strips
5.1.1.1.3 Lancets
5.1.1.2 By End User
5.1.1.2.1 Hospital (Market Size, Value and Volume)
5.1.1.2.1.1 Glucometer Devices
5.1.1.2.1.2 Test Strips
5.1.1.2.1.3 Lancets
5.1.1.2.2 Personal (Market Size, Value and Volume)
5.1.1.2.2.1 Glucometer Devices
5.1.1.2.2.2 Test Strips
5.1.1.2.2.3 Lancets
5.1.2 Continuous Blood Glucose Monitoring
5.1.2.1 By Component (Market Size, Value and Volume)
5.1.2.1.1 Sensors
5.1.2.1.2 Receivers
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Market Size, Value and Volume)
5.2.1.1.1 Self-Monitoring Blood Glucose
5.2.1.1.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.1.1.1.2 By End User (Hospital and Home)
5.2.1.1.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.1.1.2 Continuous Glucose Monitoring
5.2.1.1.2.1 By Component (Sensors and Receivers)
5.2.1.1.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.1.2 Canada (Market Size, Value and Volume)
5.2.1.2.1 Self-Monitoring Blood Glucose
5.2.1.2.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.1.2.1.2 By End User (Hospital and Home)
5.2.1.2.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.1.2.2 Continuous Glucose Monitoring
5.2.1.2.2.1 By Component (Sensors and Receivers)
5.2.1.2.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.1.3 Rest of North America (Market Size, Value and Volume)
5.2.1.3.1 Self-Monitoring Blood Glucose
5.2.1.3.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.1.3.1.2 By End User (Hospital and Home)
5.2.1.3.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.1.3.2 Continuous Glucose Monitoring
5.2.1.3.2.1 By Component (Sensors and Receivers)
5.2.1.3.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.2 Europe
5.2.2.1 France (Market Size, Value and Volume)
5.2.2.1.1 Self-Monitoring Blood Glucose
5.2.2.1.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.2.1.1.2 By End User (Hospital and Home)
5.2.2.1.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.2.1.2 Continuous Glucose Monitoring
5.2.2.1.2.1 By Component (Sensors and Receivers)
5.2.2.1.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.2.2 Germany (Market Size, Value and Volume)
5.2.2.2.1 Self-Monitoring Blood Glucose
5.2.2.2.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.2.2.1.2 By End User (Hospital and Home)
5.2.2.2.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.2.2.2 Continuous Glucose Monitoring
5.2.2.2.2.1 By Component (Sensors and Receivers)
5.2.2.2.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.2.3 Italy (Market Size, Value and Volume)
5.2.2.3.1 Self-Monitoring Blood Glucose
5.2.2.3.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.2.3.1.2 By End User (Hospital and Home)
5.2.2.3.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.2.3.2 Continuous Glucose Monitoring
5.2.2.3.2.1 By Component (Sensors and Receivers)
5.2.2.3.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.2.4 Spain (Market Size, Value and Volume)
5.2.2.4.1 Self-Monitoring Blood Glucose
5.2.2.4.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.2.4.1.2 By End User (Hospital and Home)
5.2.2.4.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.2.4.2 Continuous Glucose Monitoring
5.2.2.4.2.1 By Component (Sensors and Receivers)
5.2.2.4.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.2.5 United Kingdom (Market Size, Value and Volume)
5.2.2.5.1 Self-Monitoring Blood Glucose
5.2.2.5.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.2.5.1.2 By End User (Hospital and Home)
5.2.2.5.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.2.5.2 Continuous Glucose Monitoring
5.2.2.5.2.1 By Component (Sensors and Receivers)
5.2.2.5.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.2.6 Russia (Market Size, Value and Volume)
5.2.2.6.1 Self-Monitoring Blood Glucose
5.2.2.6.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.2.6.1.2 By End User (Hospital and Home)
5.2.2.6.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.2.6.2 Continuous Glucose Monitoring
5.2.2.6.2.1 By Component (Sensors and Receivers)
5.2.2.6.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.2.7 Rest of Europe (Market Size, Value and Volume)
5.2.2.7.1 Self-Monitoring Blood Glucose
5.2.2.7.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.2.7.1.2 By End User (Hospital and Home)
5.2.2.7.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.2.7.2 Continuous Glucose Monitoring
5.2.2.7.2.1 By Component (Sensors and Receivers)
5.2.2.7.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.3 Latin America
5.2.3.1 Mexico (Market Size, Value and Volume)
5.2.3.1.1 Self-Monitoring Blood Glucose
5.2.3.1.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.3.1.1.2 By End User (Hospital and Home)
5.2.3.1.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.3.1.2 Continuous Glucose Monitoring
5.2.3.1.2.1 By Component (Sensors and Receivers)
5.2.3.1.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.3.2 Brazil (Market Size, Value and Volume)
5.2.3.2.1 Self-Monitoring Blood Glucose
5.2.3.2.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.3.2.1.2 By End User (Hospital and Home)
5.2.3.2.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.3.2.2 Continuous Glucose Monitoring
5.2.3.2.2.1 By Component (Sensors and Receivers)
5.2.3.2.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.3.3 Rest of Latin America (Market Size, Value and Volume)
5.2.3.3.1 Self-Monitoring Blood Glucose
5.2.3.3.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.3.3.1.2 By End User (Hospital and Home)
5.2.3.3.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.3.3.2 Continuous Glucose Monitoring
5.2.3.3.2.1 By Component (Sensors and Receivers)
5.2.3.3.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.4 Asia-Pacific
5.2.4.1 Japan (Market Size, Value and Volume)
5.2.4.1.1 Self-Monitoring Blood Glucose
5.2.4.1.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.4.1.1.2 By End User (Hospital and Home)
5.2.4.1.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.1.2 Continuous Glucose Monitoring
5.2.4.1.2.1 By Component (Sensors and Receivers)
5.2.4.1.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.4.2 South Korea (Market Size, Value and Volume)
5.2.4.2.1 Self-Monitoring Blood Glucose
5.2.4.2.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.4.2.1.2 By End User (Hospital and Home)
5.2.4.2.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.2.2 Continuous Glucose Monitoring
5.2.4.2.2.1 By Component (Sensors and Receivers)
5.2.4.2.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.4.3 China (Market Size, Value and Volume)
5.2.4.3.1 Self-Monitoring Blood Glucose
5.2.4.3.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.4.3.1.2 By End User (Hospital and Home)
5.2.4.3.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.3.2 Continuous Glucose Monitoring
5.2.4.3.2.1 By Component (Sensors and Receivers)
5.2.4.3.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.4.4 India (Market Size, Value and Volume)
5.2.4.4.1 Self-Monitoring Blood Glucose
5.2.4.4.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.4.4.1.2 By End User (Hospital and Home)
5.2.4.4.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.4.2 Continuous Glucose Monitoring
5.2.4.4.2.1 By Component (Sensors and Receivers)
5.2.4.4.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.4.5 Australia (Market Size, Value and Volume)
5.2.4.5.1 Self-Monitoring Blood Glucose
5.2.4.5.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.4.5.1.2 By End User (Hospital and Home)
5.2.4.5.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.5.2 Continuous Glucose Monitoring
5.2.4.5.2.1 By Component (Sensors and Receivers)
5.2.4.5.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.4.6 Vietnam (Market Size, Value and Volume)
5.2.4.6.1 Self-Monitoring Blood Glucose
5.2.4.6.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.4.6.1.2 By End User (Hospital and Home)
5.2.4.6.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.6.2 Continuous Glucose Monitoring
5.2.4.6.2.1 By Component (Sensors and Receivers)
5.2.4.6.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.4.7 Malaysia (Market Size, Value and Volume)
5.2.4.7.1 Self-Monitoring Blood Glucose
5.2.4.7.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.4.7.1.2 By End User (Hospital and Home)
5.2.4.7.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.7.2 Continuous Glucose Monitoring
5.2.4.7.2.1 By Component (Sensors and Receivers)
5.2.4.7.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.4.8 Indonesia (Market Size, Value and Volume)
5.2.4.8.1 Self-Monitoring Blood Glucose
5.2.4.8.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.4.8.1.2 By End User (Hospital and Home)
5.2.4.8.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.8.2 Continuous Glucose Monitoring
5.2.4.8.2.1 By Component (Sensors and Receivers)
5.2.4.8.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.4.9 Philippines (Market Size, Value and Volume)
5.2.4.9.1 Self-Monitoring Blood Glucose
5.2.4.9.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.4.9.1.2 By End User (Hospital and Home)
5.2.4.9.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.9.2 Continuous Glucose Monitoring
5.2.4.9.2.1 By Component (Sensors and Receivers)
5.2.4.9.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.4.10 Thailand (Market Size, Value and Volume)
5.2.4.10.1 Self-Monitoring Blood Glucose
5.2.4.10.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.4.10.1.2 By End User (Hospital and Home)
5.2.4.10.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.10.2 Continuous Glucose Monitoring
5.2.4.10.2.1 By Component (Sensors and Receivers)
5.2.4.10.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.4.11 Rest of Asia-Pacific (Market Size, Value and Volume)
5.2.4.11.1 Self-Monitoring Blood Glucose
5.2.4.11.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.4.11.1.2 By End User (Hospital and Home)
5.2.4.11.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.4.11.2 Continuous Glucose Monitoring
5.2.4.11.2.1 By Component (Sensors and Receivers)
5.2.4.11.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.5 Middle East and Africa
5.2.5.1 Saudi Arabia (Market Size, Value and Volume)
5.2.5.1.1 Self-Monitoring Blood Glucose
5.2.5.1.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.5.1.1.2 By End User (Hospital and Home)
5.2.5.1.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.5.1.2 Continuous Glucose Monitoring
5.2.5.1.2.1 By Component (Sensors and Receivers)
5.2.5.1.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.5.2 Iran (Market Size, Value and Volume)
5.2.5.2.1 Self-Monitoring Blood Glucose
5.2.5.2.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.5.2.1.2 By End User (Hospital and Home)
5.2.5.2.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.5.2.2 Continuous Glucose Monitoring
5.2.5.2.2.1 By Component (Sensors and Receivers)
5.2.5.2.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.5.3 Egypt (Market Size, Value and Volume)
5.2.5.3.1 Self-Monitoring Blood Glucose
5.2.5.3.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.5.3.1.2 By End User (Hospital and Home)
5.2.5.3.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.5.3.2 Continuous Glucose Monitoring
5.2.5.3.2.1 By Component (Sensors and Receivers)
5.2.5.3.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.5.4 Oman (Market Size, Value and Volume)
5.2.5.4.1 Self-Monitoring Blood Glucose
5.2.5.4.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.5.4.1.2 By End User (Hospital and Home)
5.2.5.4.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.5.4.2 Continuous Glucose Monitoring
5.2.5.4.2.1 By Component (Sensors and Receivers)
5.2.5.4.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.5.5 South Africa (Market Size, Value and Volume)
5.2.5.5.1 Self-Monitoring Blood Glucose
5.2.5.5.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.5.5.1.2 By End User (Hospital and Home)
5.2.5.5.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.5.5.2 Continuous Glucose Monitoring
5.2.5.5.2.1 By Component (Sensors and Receivers)
5.2.5.5.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
5.2.5.6 Rest of Middle and Africa (Market Size, Value and Volume)
5.2.5.6.1 Self-Monitoring Blood Glucose
5.2.5.6.1.1 By Component (Glucometer Device, Test strips, Lancets)
5.2.5.6.1.2 By End User (Hospital and Home)
5.2.5.6.1.3 By Company (Roche, Abbott, Johnson & Johnson and Others)
5.2.5.6.2 Continuous Glucose Monitoring
5.2.5.6.2.1 By Component (Sensors and Receivers)
5.2.5.6.2.2 By Company (Dexcom, Abbott, Medtronic and Others)
6 MARKET INDICATORS
6.1 Type-1 Diabetes population (2013-2024)
6.2 Type-2 Diabetes population (2013-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Abbott Diabetes Care
7.1.2 Roche
7.1.3 Johnson & Johnson
7.1.4 Dexcom
7.1.5 Medtronic
7.1.6 Arkray
7.1.7 Ascensia Diabetes Care
7.1.8 Agamatrix Inc.
7.1.9 Bionime Corporation
7.1.10 Acon
7.1.11 Medisana
7.1.12 Trivida
7.1.13 Rossmax
7.2 COMPANY SHARE ANALYSIS
7.2.1 Roche
7.2.2 Johnson & Johnson
7.2.3 Abbott Diabetes Care
7.2.4 Dexcom
7.2.5 Medtronic
7.2.6 Others
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Blood Glucose Monitoring
Self-Monitoring Blood Glucose
By Component (Market Size, Value and Volume)
Glucometer Devices
Test Strips
Lancets
By End User
Hospital (Market Size, Value and Volume)
Glucometer Devices
Test Strips
Lancets
Personal (Market Size, Value and Volume)
Glucometer Devices
Test Strips
Lancets
Continuous Blood Glucose Monitoring
By Component (Market Size, Value and Volume)
Sensors
Receivers
Geography
North America
United States (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Canada (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Rest of North America (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Europe
France (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Germany (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Italy (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Spain (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
United Kingdom (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Russia (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Rest of Europe (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Latin America
Mexico (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Brazil (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Rest of Latin America (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Asia-Pacific
Japan (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
South Korea (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
China (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
India (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Australia (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Vietnam (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Malaysia (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Indonesia (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Philippines (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Thailand (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Rest of Asia-Pacific (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Middle East and Africa
Saudi Arabia (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Iran (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Egypt (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Oman (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
South Africa (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Rest of Middle and Africa (Market Size, Value and Volume)
Self-Monitoring Blood Glucose
By Component (Glucometer Device, Test strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson and Others)
Continuous Glucose Monitoring
By Component (Sensors and Receivers)
By Company (Dexcom, Abbott, Medtronic and Others)
Blood Glucose Test Strips Market (2012 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 105 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 105 pages
- Published: 12-06-2019
Market Overview
As a part of diabetes treatment, constant monitoring of glucose levels is required. Blood glucose levels if not monitored regularly can lead to severe complications. Diabetes management process is an expensive service. At the large scale, patients use blood glucose test strips. The retail cost of these strips varies from 50 cents per piece to as high as USD 5 per strip.
Price is often a significant concern for the purchase of blood glucose test strips. Although various countries, like the United Kingdom, provide reimbursements for prescribed test strips, the majority of the patients have to pay for them from their pockets.
The frequency of monitoring glucose levels depends on the type of diabetes and varies from patient to patient.
Type 1 diabetic patients need to check their blood glucose levels at regular intervals to monitor their blood glucose levels and adjust the insulin dosing accordingly.
Therefore, if a patient performs 5-6 tests in a day, the average expenditure on test strips would be over USD 180/month. These expenses add to the already high diabetes management costs and are impeding the market growth.
Scope of the Report
In 2018, the global blood glucose test strips market was estimated at around USD 8,022.8 million. The market is expected to register a CAGR of about 10.8 % during the forecast period (2019-2024). The market is segmented by component (blood glucose test strips), end user (hospital and personal use test strips), and geography.
Key Market Trends –
Increased Awareness Among Type 2 Diabetic Patients is Driving the Blood Glucose Test Strips Market
Due to the ease in handling glucometers, patients are now preferring to use them for their personal use (home use).
Measuring blood glucose levels is essential to take or alter the medication accordingly, especially insulin users. Within seconds, glucometers provide the blood glucose levels with accuracy. There is constant upgradation in glucometers for better use and more efficiency.
Approximately 10% of diabetic population contributes to Type 1 diabetes and 90% contributes to Type 2 diabetes.
About 90% of Type 1 patients are using glucometer in their daily routines, and 25% of Type 2 patients are using the glucometers.
Due to the sedentary lifestyle, the blood glucose levels for Type 2 diabetes patients are not under control, and this is causing the patients to regularly monitor their blood glucose levels to avoid further complications of diabetes.
Thus, the aforementioned factor has increased the demand for the blood glucose test strips market.
North America to Dominate the Market
Globally, North America accounted for the largest share of 58.33% in 2017, owing to the availability of healthcare reimbursements and the fastest adoption rate for new medical technologies.
Europe is also a leading region in the global blood glucose test strips market. North America is the fastest-growing region for the market and portrays a massive potential for growth in the future, due to the increasing government initiatives to combat diabetes and corporate investments to streamline R&D in diabetes.
Competitive Landscape
The global blood glucose test strips market is highly fragmented, with few major manufacturers having presence in major regions of the global market, while the remaining manufacturers confine to the other local or region-specific manufacturers.
The innovations in test strips are increasing and are under development. For example, the new test strip includes features, such as underfill detection, and provides the user with the ability to reapply blood when the test strip is underfilled (“second chance” sampling).
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Component (Value and Volume, 2012-2024)
5.1.1 Blood Glucose Test Strips
5.2 By End User
5.2.1 Hospital (Value and Volume, 2012-2024)
5.2.2 Personal (Value and Volume, 2012-2024)
5.3 Geography
5.3.1 North America
5.3.1.1 United States (Value and Volume, 2012-2024)
5.3.1.1.1 By Component (Blood Glucose Test Strips)
5.3.1.1.2 By End User (Hospital and Home)
5.3.1.2 Canada (Value and Volume, 2012-2024)
5.3.1.2.1 By Component (Blood Glucose Test Strips)
5.3.1.2.2 By End User (Hospital and Home)
5.3.1.3 Rest of North America (Value and Volume, 2012-2024)
5.3.1.3.1 By Component (Blood Glucose Test Strips)
5.3.1.3.2 By End User (Hospital and Home)
5.3.2 Europe
5.3.2.1 France (Value and Volume, 2012-2024)
5.3.2.1.1 By Component (Blood Glucose Test Strips)
5.3.2.1.2 By End User (Hospital and Home)
5.3.2.2 Germany (Value and Volume, 2012-2024)
5.3.2.2.1 By Component (Blood Glucose Test Strips)
5.3.2.2.2 By End User (Hospital and Home)
5.3.2.3 Italy (Value and Volume, 2012-2024)
5.3.2.3.1 By Component (Blood Glucose Test Strips)
5.3.2.3.2 By End User (Hospital and Home)
5.3.2.4 Spain (Value and Volume, 2012-2024)
5.3.2.4.1 By Component (Blood Glucose Test Strips)
5.3.2.4.2 By End User (Hospital and Home)
5.3.2.5 United Kingdom (Value and Volume, 2012-2024)
5.3.2.5.1 By Component (Blood Glucose Test Strips)
5.3.2.5.2 By End User (Hospital and Home)
5.3.2.6 Russia (Value and Volume, 2012-2024)
5.3.2.6.1 By Component (Blood Glucose Test Strips)
5.3.2.6.2 By End User (Hospital and Home)
5.3.2.7 Rest of Europe (Value and Volume, 2012-2024)
5.3.2.7.1 By Component (Blood Glucose Test Strips)
5.3.2.7.2 By End User (Hospital and Home)
5.3.3 Latin America
5.3.3.1 Mexico (Value and Volume, 2012-2024)
5.3.3.1.1 By Component (Blood Glucose Test Strips)
5.3.3.1.2 By End User (Hospital and Home)
5.3.3.2 Brazil (Value and Volume, 2012-2024)
5.3.3.2.1 By Component (Blood Glucose Test Strips)
5.3.3.2.2 By End User (Hospital and Home)
5.3.3.3 Rest of Latin America (Value and Volume, 2012-2024)
5.3.3.3.1 By Component (Blood Glucose Test Strips)
5.3.3.3.2 By End User (Hospital and Home)
5.3.4 Asia-Pacific
5.3.4.1 Japan (Value and Volume, 2012-2024)
5.3.4.1.1 By Component (Blood Glucose Test Strips)
5.3.4.1.2 By End User (Hospital and Home)
5.3.4.2 South Korea (Value and Volume, 2012-2024)
5.3.4.2.1 By Component (Blood Glucose Test Strips)
5.3.4.2.2 By End User (Hospital and Home)
5.3.4.3 China (Value and Volume, 2012-2024)
5.3.4.3.1 By Component (Blood Glucose Test Strips)
5.3.4.3.2 By End User (Hospital and Home)
5.3.4.4 India (Value and Volume, 2012-2024)
5.3.4.4.1 By Component (Blood Glucose Test Strips)
5.3.4.4.2 By End User (Hospital and Home)
5.3.4.5 Australia (Value and Volume, 2012-2024)
5.3.4.5.1 By Component (Blood Glucose Test Strips)
5.3.4.5.2 By End User (Hospital and Home)
5.3.4.6 Vietnam (Value and Volume, 2012-2024)
5.3.4.6.1 By Component (Blood Glucose Test Strips)
5.3.4.6.2 By End User (Hospital and Home)
5.3.4.7 Malaysia (Value and Volume, 2012-2024)
5.3.4.7.1 By Component (Blood Glucose Test Strips)
5.3.4.7.2 By End User (Hospital and Home)
5.3.4.8 Indonesia (Value and Volume, 2012-2024)
5.3.4.8.1 By Component (Blood Glucose Test Strips)
5.3.4.8.2 By End User (Hospital and Home)
5.3.4.9 Philippines (Value and Volume, 2012-2024)
5.3.4.9.1 By Component (Blood Glucose Test Strips)
5.3.4.9.2 By End User (Hospital and Home)
5.3.4.10 Thailand (Value and Volume, 2012-2024)
5.3.4.10.1 By Component (Blood Glucose Test Strips)
5.3.4.10.2 By End User (Hospital and Home)
5.3.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2024)
5.3.4.11.1 By Component (Blood Glucose Test Strips)
5.3.4.11.2 By End User (Hospital and Home)
5.3.5 Middle East & Africa
5.3.5.1 Saudi Arabia (Value and Volume, 2012-2024)
5.3.5.1.1 By Component (Blood Glucose Test Strips)
5.3.5.1.2 By End User (Hospital and Home)
5.3.5.2 Iran (Value and Volume, 2012-2024)
5.3.5.2.1 By Component (Blood Glucose Test Strips)
5.3.5.2.2 By End User (Hospital and Home)
5.3.5.3 Egypt (Value and Volume, 2012-2024)
5.3.5.3.1 By Component (Blood Glucose Test Strips)
5.3.5.3.2 By End User (Hospital and Home)
5.3.5.4 Oman (Value and Volume, 2012-2024)
5.3.5.4.1 By Component (Blood Glucose Test Strips)
5.3.5.4.2 By End User (Hospital and Home)
5.3.5.5 South Africa (Value and Volume, 2012-2024)
5.3.5.5.1 By Component (Blood Glucose Test Strips)
5.3.5.5.2 By End User (Hospital and Home)
5.3.5.6 Rest of Middle & Africa (Value and Volume, 2012-2024)
5.3.5.6.1 By Component (Blood Glucose Test Strips)
5.3.5.6.2 By End User (Hospital and Home)
6 MARKET INDICATORS
6.1 Type 1 Diabetes Population (2012-2024)
6.2 Type 2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Abbott Diabetes Care
7.1.2 Roche
7.1.3 Johnson & Johnson
7.1.4 Arkray
7.1.5 Ascensia Diabetes Care
7.1.6 Agamatrix Inc.
7.1.7 Bionime Corporation
7.1.8 Acon
7.1.9 Trivida
7.1.10 Rossmax
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Component (Value and Volume, 2012-2024)
Blood Glucose Test Strips
By End User
Hospital (Value and Volume, 2012-2024)
Personal (Value and Volume, 2012-2024)
Geography
North America
United States (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Canada (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Rest of North America (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Europe
France (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Germany (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Italy (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Spain (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
United Kingdom (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Russia (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Rest of Europe (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Latin America
Mexico (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Brazil (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Rest of Latin America (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Asia-Pacific
Japan (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
South Korea (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
China (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
India (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Australia (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Vietnam (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Malaysia (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Indonesia (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Philippines (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Thailand (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Rest of Asia-Pacific (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Middle East & Africa
Saudi Arabia (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Iran (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Egypt (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Oman (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
South Africa (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Rest of Middle & Africa (Value and Volume, 2012-2024)
By Component (Blood Glucose Test Strips)
By End User (Hospital and Home)
Bone Cancer Treatment Market- Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 120 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 120 pages
- Published: 07-06-2019
Market Overview
The global bone cancer treatment market was valued at USD 62,865.6 million in 2018, and it is estimated to be valued at USD 83,770.9 million in 2024 while witnessing a CAGR of 4.93%. Certain factors that are driving the market growth include increasing incidence of bone cancer and increasing government initiatives for bone cancer awareness. The incidences of bone cancer are on a steady rise and need to be wisely addressed at the earliest, in order to reduce the burden of bone sarcoma across the world.
According to the estimates by the American Society of Clinical Oncology, the United States was expected to witness 3,450 new cases of bone cancer and an expected 1,590 deaths due to bone cancer in 2018. Moreover, it is important to assure timely diagnosis and treatment, in order to increase the survival rate. Many government organizations are taking initiatives to increase awareness of bone cancer. For instance, the UK Government formed an organization named Genomics England, post the launch of the 100,000 Genomes Project in 2012. Genomic England is responsible for sequencing 100,000 genomes from 700,000 genomes of NHS-registered patients.
However, the chemotherapeutic drugs approved for the treatment of bone cancer do not have an effective treatment regime, as it always varies according to the prevailing conditions, and the way the patient’s body responds to the drug. The associated side effects, risks, and limitations of the treatment are limiting the growth of the global bone cancer treatment drugs market.
Scope of the Report
Bone cancer refers to a malignant tumor that arises from cells of bones of the body. It is also known as primary bone cancer, as it originates in the bones. Secondary bone cancer refers to a tumor that has spread to the bone area but originated elsewhere. In this report, a detailed analysis of the bone cancer treatment market is presented, with specific attention on primary bone cancer.
Key Market Trends
Osteosarcoma is Expected to Hold the Largest Market Share in the Primary Bone Cancer Type
In the bone cancer type segment of the bone cancer treatment market, among all primary bone cancers, osteosarcoma is expected to have largest market size and is likely to witness a CAGR of 6.31% over the forecast period. Osteosarcoma is the most common type of cancer affecting bones, and it mostly occurs in children and young adults. Based on the cells, osteosarcoma is classified as high-, intermediate- and low-grade. According to the American Cancer Society, about 800 to 900 new cases of osteosarcoma are diagnosed in the United States every year, with about half of these occurring in children and teenagers.
Research on osteosarcoma is done at various medical centers, university hospitals, and other institutions across the world. Many advancements have taken place in the treatment of osteosarcoma in the past few decades. Osteosarcoma can be treated by surgery, radiation therapy, chemotherapy, targeted therapy drugs, etc. Thus, research related to the bone cancer treatment market is increasing, owing to the high prevalence of osteosarcoma, globally.
North America Dominates the Market and is Expected to do Same in the Forecast Period
North America currently dominates the bone cancer treatment market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the fact that, currently, in the region, mainly in the United States, many clinical trials are underway for bone cancer therapies. Some studies are testing new chemo drugs. Researchers are also looking for new ways to use the existing approved drug portfolio. For instance, doctors are studying whether adding a bisphosphonate called zoledronic acid (Zometa) to the bone cement, which is used in filling the space left after removing a giant cell tumor, may decrease the chances of that tumor returning in that place.
Competitive Landscape
The global bone cancer treatment market is highly competitive and consists of a considerable number of significant players. All of the existing players in global bone cancer treatment market are either legacy suppliers of treatment options, like chemotherapy and radiation therapy, or are concentrating on clinical trials for novel bone cancer approaches, including targeted therapy and immunotherapy. Companies, like Bayer AG, Amgen, Novartis AG, and Pfizer Inc., among others, are expected to hold the substantial market share in the bone cancer treatment market.
Various developments have recently been taking place in the market. For example, in September 2016, Dr. Reddy’s Laboratories (DRL) expanded strategic collaboration with Amgen to market and distribute Xgeva (denosumab), Vectibix (panitumumab), and Prolia (denosumab) in India.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Bone Cancer
4.2.2 Increasing Government Initiatives for Bone Cancer Awareness
4.3 Market Restraints
4.3.1 Unavailability of Effective Treatment and Side Effects
4.3.2 High Cost of Cancer Therapies
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 Bone Cancer Type
5.1.1 Primary Bone Cancer
5.1.1.1 Osteosarcoma
5.1.1.2 Chondrosarcoma
5.1.1.3 Ewing Tumour
5.1.1.4 Others
5.1.2 Secondary Bone Cancer (Metastatic Bone Cancer)
5.2 Treatment Type
5.2.1 Chemotherapy
5.2.1.1 Doxorubicin
5.2.1.2 Cisplatin
5.2.1.3 Cyclophosphamide
5.2.1.4 Etoposide
5.2.1.5 Other Chemotherapies
5.2.2 Targeted Therapy
5.2.2.1 Denosumab
5.2.2.2 Imatinib
5.2.3 Radiation Therapy
5.2.4 Surgery
5.2.5 Other Treatments
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 Amgen
6.1.2 Baxter
6.1.3 Bayer AG
6.1.4 Hikma Pharmaceuticals
6.1.5 Johnson & Johnson
6.1.6 Novartis AG
6.1.7 Pfizer Inc.
6.1.8 Recordati Group
6.1.9 Takeda Pharmaceutical Company
7. Market Opportunities and Future Trends
Market Segmentation
- Bone Cancer Type
Primary Bone Cancer
Osteosarcoma
Chondrosarcoma
Ewing Tumour
Others
Secondary Bone Cancer (Metastatic Bone Cancer)
Treatment Type
Chemotherapy
Doxorubicin
Cisplatin
Cyclophosphamide
Etoposide
Other Chemotherapies
Targeted Therapy
Denosumab
Imatinib
Radiation Therapy
Surgery
Other Treatments
Geography
North America
United States
Canada
Mexico - Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Brain Monitoring Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 112 pages | Published: 10-06-2019 |
- Healthcare
- Mordor Intelligence
- 112 pages
- Published: 10-06-2019
Market Overview
The global brain monitoring market was valued at USD 1,514.52 million in 2018, and is estimated to be valued at USD 2,430.18 million in 2024, witnessing a CAGR of 8.20%. The key factors propelling the growth of this market are ageing demographic, rising incidence of brain disorders, and ease of use and portability of devices. The initial models of EEG monitors were loaded with wires and electrodes, and even in current practice, a vast majority of devices are based on this conventional architecture. But with the advent of wireless technology, the size and clumsiness of EEG monitors and other related devices have been drastically reduced. Wireless monitors are devices that do not require wired connections or cords for diagnosis. Nowadays, wireless headsets allow readings to be done completely in a non-invasive way, and in some cases, assess patients from the comfort of their homes. Wireless technology mainly allows the recording device to be detached from the computer and communicate through wireless signals to the computer from a distance of up to 10 or 20 meters. These devices are simple, affordable, and comfortable to wear and are powered by a single AAA battery. Portable brain monitoring devices are lightweight, easy to carry, and can be held in the hand.
Thus, the portability of such devices is propelling the growth of the market, as people are moving toward handier and easy-to-access types of devices.
Scope of the Report
The global brain monitoring market report analyzes the market trends of various brain monitoring devices, in addition to the future growth and regional markets of the same. As per the scope of the report, the market has been segmented based on product, modality, end user, and geography.
Key Market Trends
Electroencephalograph is Expected to hold its Highest Market Share in the Product Type Segment
Under the product type segmentation of the market, electroencephalograph is believed to have the largest market size and is expected to witness a CAGR of 8.25%, during the forecast period.
Electroencephalography (EEG) is the recording of electrical activity along the scalp, produced by the firing of neurons within the brain. In clinical contexts, EEG refers to the recording of the brain’s spontaneous electrical activity over a short period of time, usually 20and 40 minutes, as recorded from multiple electrodes placed on the scalp. In neurology, the main diagnostic application of EEG is in the case of epilepsy, as epileptic activity can create clear abnormalities on a standard EEG study. A secondary clinical use of EEG is in the diagnosis of coma, encephalopathy, and brain death. Recently, Masimo got FDA clearance for next-generation SedLine brain function monitoring. SedLine helps clinicians monitor the state of the brain under anesthesia, with bilateral acquisition and processing of four leads of electroencephalogram (EEG) signals.
Increasing brain disorders and increasing technological advancements are driving the EEG market and are expected to further increase in the coming years.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America currently dominates the market for brain monitoring and is expected to continue its stronghold for a few more years. The United States holds the largest share of the global brain monitoring market. According to the US National Institute of Mental Health (NIMH), it has been estimated that one in four American adults suffer from a diagnosable mental disorder in any given year, and nearly 6% suffer from serious disabilities. The same source has also stated that the total cost of serious mental illness in the United States exceeds USD 317 billion, per year.
Factors, such as favorable reimbursement policies, increasing technological advancements (including the development of mobile EEG machines, real-time monitoring, and alerts) have driven the growth of the market in the United States.
Competitive Landscape
The brain monitoring market is moderately competitive and consists of several major and small industry players. In terms of market share, few of the major players currently dominate the market in specific segments. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new technologies with better usability. Companies, like Medtronic PLC, Integra LifeSciences Corporation, Nihon Kohden Corporation, Masimo Corporation, and Natus Medical Incorporated, hold a substantial market share in the brain monitoring market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Aging Demographic
4.2.2 Rise in Incidences of Brain Disorders
4.2.3 Ease of Use and Portability of Devices
4.3 Market Restraints
4.3.1 Regulatory Approval Costs
4.3.2 Lack of Skilled Personnel to Handle Devices
4.3.3 Intra-operative Awareness
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Magnetoencephalograph
5.1.2 Electroencephalograph
5.1.3 Oximeters
5.1.4 Doppler Devices
5.1.5 Pressure Monitors
5.1.6 Other Product Types
5.2 By Modality
5.2.1 Portable Devices
5.2.2 Fixed Devices
5.3 By End User
5.3.1 Hospitals
5.3.2 Diagnostic Centers
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Natus Medical Incorporated
6.1.2 Medtronic PLC
6.1.3 Integra Lifesciences Holding Corporation (Integra Lifesciences)
6.1.4 Compumedics
6.1.5 Nihon Kohden Corporation
6.1.6 Masimo Corporation
6.1.7 Elekta AB
6.1.8 Advanced Brain Monitoring Inc.
6.1.9 Cadwell Laboratories
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Product Type
Magnetoencephalograph
Electroencephalograph
Oximeters
Doppler Devices
Pressure Monitors
Other Product Types
By Modality
Portable Devices
Fixed Devices
By End User
Hospitals
Diagnostic Centers
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Cancer Therapy Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 117 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 117 pages
- Published: 07-06-2019
Market Overview
The global cancer therapy market was valued at USD 136,254.35 million in 2018, and is estimated to be valued at USD 220,701.26 million in 2024, witnessing a CAGR of 8.37%. Certain factors that are driving the market growth include increasing Patient Assistance Programs (PAPs), increasing government initiatives for cancer awareness, rising prevalence of cancer worldwide, and strong R&D initiatives from key players.
More than 45 million Americans do not have health insurance and millions more are underinsured; eight out of 10 uninsured people are from working families. Among those with health insurance, one out of 10 individuals, 65 years old or younger, and one in three persons over 65 years do not have prescription drug coverage. Hence, Patients Assistance Programs (PAPs) have emerged in an effort to help patients who are lacking health insurance or prescription drug coverage get the medication they need. These programs are provided by pharmaceutical companies to provide free or low-cost prescription drugs to patients who are suffering from serious illnesses.
Several big pharmaceutical companies, such as Pfizer and Eli lily, have also started these programs to help uninsured patients who are suffering from chronic diseases. Thus, a large number of uninsured patients, suffering from cancer, can also undergo cancer therapies, which is likely to augment the growth of the market.
Scope of the Report
As per the scope of the report, cancer therapies are drugs that block the growth and proliferation of cancer, by interfering with specific molecules, such as DNA or proteins, which are involved in the growth or expansion of cancerous cells. These therapies include surgery, radiation therapy, chemotherapy, immunotherapy, etc.
Key Market Trends
The Target Therapy Segment is Expected to show the Fastest Growth in the Forecast Period
The target therapy segment is expected to show the highest CAGR of 9.68% during the forecast period. The target therapy includes hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules. Targeted therapy is attaining importance due to its specificity toward cancer cells, while sparing the toxicity to off-target cells.
The breast cancer segment is belived to account for the largest market size over the forecast period. This is majorly attrobuted to the higher and continuously increaisng prevalence of breast cancer acoss the world. As per estimates provided by the Breast Cancer Organization in 2018, it is estimated that over 2,66,120 new cases of invasive breast cancer are expected to be diagnosed in women in the United States, along with 63,960 new cases of non-invasive (in situ) breast cancer.
North America Currently Dominates the Cancer Therapy Market and is Expected to Continue in the Forecast Period
North America currently dominates the market for cancer therapy and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the increased adoption of cancer therapy. The United States holds majority of the market in the North American region, due to the rising prevalence of cancer in the country. According to the National Cancer Institute (NCI), in 2016, 1.6 million people suffered from cancer, and around 0.5 million people died from cancer. This figure indicates that the prevalence of cancer is rapidly increasing in the United States.
Competitive Landscape
The cancer therapy market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence, by introducing new products with cheaper prices. Companies, like Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, and Johnson and Johnson, hold significant shares in the cancer therapy market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Patient Assistance Programs (PAPs)
4.2.2 Growing Government Initiatives for Cancer Awareness
4.2.3 Rising Prevalence of Cancer Worldwide
4.2.4 Strong R&D Initiatives from Key Players
4.3 Market Restraints
4.3.1 Fluctuation in Reimbursement Policies
4.3.2 High Cost of Cancer Therapies
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Treatment Type
5.1.1 Chemotherapy
5.1.2 Targeted Therapy
5.1.3 Immunotherapy
5.1.4 Hormonal Therapy
5.1.5 Other Treatment Types
5.2 By Cancer Type
5.2.1 Blood Cancer
5.2.2 Breast Cancer
5.2.3 Prostate Cancer
5.2.4 Gastrointestinal Cancer
5.2.5 Gynecologic Cancer
5.2.6 Respiratory/Lung Cancer
5.2.7 Other Cancer Types
5.3 By End User
5.3.1 Hospitals
5.3.2 Spcialty Clinics
5.3.3 Cancer and Radiation Therapy Centers
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 South Korea
5.4.3.5 Australia
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amgen Inc.
6.1.2 AstraZeneca PLC
6.1.3 Bayer AG
6.1.4 Johnson and Johnson
6.1.5 Merck & Co. Inc.
6.1.6 F. Hoffmann-La Roche AG
6.1.7 Eli Lilly and Company
6.1.8 Novartis AG
6.1.9 Pfizer Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Treatment Type
Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Other Treatment Types
By Cancer Type
Blood Cancer
Breast Cancer
Prostate Cancer
Gastrointestinal Cancer
Gynecologic Cancer
Respiratory/Lung Cancer
Other Cancer Types
By End User
Hospitals
Spcialty Clinics
Cancer and Radiation Therapy Centers
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Carrier Screening Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 114 pages | Published: 10-06-2019 |
- Healthcare
- Mordor Intelligence
- 114 pages
- Published: 10-06-2019
Market Overview
The major factors for the growth of the carrier screening market include the increasing emphasis on early disease detection and prevention, rising demand for personalized medicine, and increasing application of screening tests in genetic disorders, which is expected to experience a boost during the forecast period.
The earlier a disease is diagnosed, the more likely it can be cured or successfully managed. Treating the disease early could also make the disease easier to live with. Early disease detection helps people plan ahead, while they are still able to make important decisions regarding their health and support needs and on financial and legal matters. Genetic diseases, such as cystic fibrosis, sickle cell anemia, and Tay-Sachs disease, are inherited disorders. Carrier testing for such diseases can provide information about a couple’s risk of having a child with a genetic condition. Identification of the risk, prior to the onset of symptoms, is called predictive/presymptomatic testing. Many genetic disorders can be detected early during pregnancy. So, the consumer demand for safe and effective carrier tests is fueling the growth of this market. In addition, the adoption of carrier tests into regular clinical care offers a commercial advantage to the market. According to many studies, early detection of diseases can prevent them completely or at least decrease the complications of the diseases. Healthcare organizations in several countries are funding newborn screening to predict diseases, like cancers, which may occur later in adulthood.
Scope of the Report
As per the scope of the report, carrier screening is a type of genetic test to identify the autosomal recessive genetic disorders, before or during a pregnancy stage. Further, it helps in identifying a child with a genetic disorder. The market is segmented on the basis of screening test type (molecular screening test/biochemical screening test), disease type (cystic fibrosis, Tay-Sachs disease, sickle cell disease, gaucher disease, spinal muscular atrophy, and other autosomal recessive genetic disorders). In developed countries, such as the United States, Germany, and France, among others, the demand for screening tests to detect the risk of genetic diseases is driving the market’s growth.
Key Market Trends
Molecular Screening Test Segment by Test Type is Expected to Register Fastest Growth Rate during the Forecast Period
A molecular screening test identifies DNA mutations, which are variations in the genetic code that lead to decreased production of enzymes. It focuses on the mutations seen in one ethnic group. It involves a step-wise process of testing for common alleles, and if required, extensive gene analysis. Sequencing is a method of molecular screening, which is accomplished by reading across the DNA code of a specific gene to know if there are any known mutations. If the test results are negative, it reduces the chances that the individual is a carrier, however, it does not eliminate the chance of having a carrier gene, since it is possible that the mutation might not have been discovered yet through the current technology.
Some of the prominent recessive disorders for which molecular testing is beneficial are Canavan disease, Cystic fibrosis, GM1 gangliosidosis, spinal muscular atrophy, etc. With advancements in genetic analysis tools, like assays based on next-generation sequencing and microarray technologies, molecular diagnostics are revolutionizing the practice of medicine, by improving the prenatal and reproductive care, enabling earlier disease detection, and advancing the treatment for heritable diseases. There is an expansion of molecular testing, as it has the potential to increase testing accuracies through technical benefits for many targeted disorders that may not be suggested to biochemical testing.
North America accounted for the Largest Share in the Global Market
North America is found to hold a major share of the carrier screening market and is expected to show a similar trend over the forecast period, without significant fluctuations. Genetic disease is the leading cause of infant deaths in the United States, accounting for approximately 20% of the total annual infant mortality. Many advances in genomic medicine and technological platforms have made possible low-cost, panâ€ethnic, expanded carrier screening that enables obstetric care providers to offer screening for over 100 recessive genetic diseases. However, the rapid integration of this genomic medicine into the routine obstetric practice has raised some concerns about the practical implementation of carrier testing. According to the Cystic Fibrosis Foundation, more than 30,000 people suffer from cystic fibrosis in the United States, and approximately 1,000 new cases of cystic fibrosis are diagnosed each year in the country. Thus, as the prevalence of genetic diseases is increasing every year, the usage of carrier screening is also expected to increase during the forecast period.
Competitive Landscape
The presence of major market players, such as Abbott, F. Hoffmann-La Roche AG, Cepheid (Danaher Corporation), Illumina Inc., and Thermo Fisher Scientific Inc, in turn, is increasing the overall competitive rivalry of the market. Most of the market players are expanding their technologies through acquisitions and partnerships. For instance, in January 2017, Philips and Illumina collaborated to offer the integrated genomics solutions for oncology.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Emphasis on Early Disease Detection and Prevention
4.2.2 Rising Demand for Personalized Medicine
4.2.3 Increasing Application of Screening Tests in Genetic Disorders
4.3 Market Restraints
4.3.1 Social and Ethical Implications of Carrier Screening
4.3.2 High Costs of Carrier Testing
4.3.3 Reimbursement Issues
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Test Type
5.1.1 Molecular Screening Test
5.1.2 Biochemical Screening Test
5.2 Disease Type
5.2.1 Cystic Fibrosis
5.2.2 Tay-Sachs
5.2.3 Gaucher Disease
5.2.4 Sickle Cell Disease
5.2.5 Spinal Muscular Atrophy
5.2.6 Other Autosomal Recessive Genetic Disorders
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 23Andme Inc.
6.1.2 Abbott Laboratories
6.1.3 F. Hoffmann-La Roche AG
6.1.4 Cepheid (Danaher Corporation)
6.1.5 Illumina Inc.
6.1.6 Luminex Corporation
6.1.7 Sequenom Inc. (Laboratory Corporation of America�Holdings)
6.1.8 Myriad Genetics
6.1.9 Autogenomics Inc.
6.1.10 Thermo Fisher Scientific Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Test Type
Molecular Screening Test
Biochemical Screening Test
Disease Type
Cystic Fibrosis
Tay-Sachs
Gaucher Disease
Sickle Cell Disease
Spinal Muscular Atrophy
Other Autosomal Recessive Genetic Disorders
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America